Entity Central Index Key
Amount of accumulated amortization of intangible assets, excluding goodwill.
Cover [Abstract]
Document Type
Document Type
Amendment Flag
Amendment Flag
Document Quarterly Report
Document Quarterly Report
Document Period End Date
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Document Transition Report
Document Transition Report
Entity File Number
Entity File Number
Entity Registrant Name
Entity Registrant Name
Entity Incorporation, State or Country Code
Entity Incorporation State Country Code
Entity Tax Identification Number
Entity Tax Identification Number
Entity Address, Address Line One
Entity Address Address Line1
Entity Address, Address Line Two
Entity Address Address Line2
Entity Address, City or Town
Entity Address City Or Town
Entity Address, State or Province
Entity Address State Or Province
Entity Address, Postal Zip Code
Entity Address Postal Zip Code
City Area Code
City Area Code
Local Phone Number
Local Phone Number
Title of 12(b) Security
Security12b Title
Trading Symbol
Trading Symbol
Security Exchange Name
Security Exchange Name
Entity Current Reporting Status
Entity Current Reporting Status
Entity Interactive Data Current
Entity Interactive Data Current
Entity Filer Category
Entity Filer Category
Entity Small Business
Entity Small Business
Entity Emerging Growth Company
Entity Emerging Growth Company
Entity Ex Transition Period
Entity Ex Transition Period
Entity Shell Company
Entity Shell Company
Entity Common Stock, Shares Outstanding
Entity Common Stock Shares Outstanding
Statement Of Financial Position [Abstract]
Assets
Assets [Abstract]
Current assets
Assets Current [Abstract]
Cash and cash equivalents
Cash And Cash Equivalents At Carrying Value
Accounts receivable, net
Accounts Receivable Net Current
Other current assets
Other Assets Current
Total current assets
Assets Current
Non‑current assets
Assets Noncurrent [Abstract]
Property and equipment, net
Property Plant And Equipment Net
Intangible assets, net
Intangible Assets Net Excluding Goodwill
Other long-term assets
Other Assets Noncurrent
Goodwill
Goodwill
Total non‑current assets
Assets Noncurrent
Total assets
Assets
Liabilities and Stockholders' Equity
Liabilities And Stockholders Equity [Abstract]
Current liabilities
Liabilities Current [Abstract]
Accounts payable
Accounts Payable Current
Accrued liabilities
Accrued Liabilities Current
Deferred revenue
Contract With Customer Liability Current
Current portion of notes payable
Notes Payable To Bank Current
Total current liabilities
Liabilities Current
Non‑current liabilities
Liabilities Noncurrent [Abstract]
Long‑term notes payable
Long Term Notes Payable
Contingent consideration
Business Combination Contingent Consideration Liability Noncurrent
Other long-term liabilities
Other Liabilities Noncurrent
Total non‑current liabilities
Liabilities Noncurrent
Total liabilities
Liabilities
Commitments and contingencies
Commitments And Contingencies
Stockholders' equity
Stockholders Equity [Abstract]
Preferred stock, $0.001 par value, 5,000,000 shares authorized; 0 (2021 and 2020) shares issued and outstanding
Preferred Stock Value
Common stock, $0.001 par value, 200,000,000 shares authorized; 26,785,431 (2021) and 26,561,504 (2020) shares issued and outstanding
Common Stock Value
Additional paid‑in capital
Additional Paid In Capital
Accumulated deficit
Retained Earnings Accumulated Deficit
Total stockholders' equity
Stockholders Equity
Total liabilities and stockholders' equity
Liabilities And Stockholders Equity
Preferred stock, par value
Preferred Stock Par Or Stated Value Per Share
Preferred stock, authorized
Preferred Stock Shares Authorized
Preferred stock, issued
Preferred Stock Shares Issued
Preferred stock, outstanding
Preferred Stock Shares Outstanding
Common stock, par value
Common Stock Par Or Stated Value Per Share
Common stock, authorized
Common Stock Shares Authorized
Common stock, issued
Common Stock Shares Issued
Common stock, outstanding
Common Stock Shares Outstanding
Direct costs and expenses.
Change in fair value of contingent consideration excluding accretion expense.
Income Statement [Abstract]
Revenues
Revenues
Operating expenses:
Operating Expenses [Abstract]
Direct costs and expenses
Direct Costs And Expenses
Research and development
Research And Development Expense
Sales, marketing, general and administrative
Selling General And Administrative Expense
Change in fair value of contingent consideration
Change In Fair Value Of Contingent Consideration Excluding Accretion Expense
Total operating expenses
Operating Expenses
Loss from operations
Operating Income Loss
Other income (expense):
Other Income And Expenses [Abstract]
Interest expense
Interest Expense
Change in fair value of warrant liability
Fair Value Adjustment Of Warrants
Loss on debt extinguishment
Gains Losses On Extinguishment Of Debt
Other income, net
Other Nonoperating Income
Total other expense
Other Nonoperating Income Expense
Net loss
Net Income Loss
Net loss per share, basic and diluted
Earnings Per Share Basic And Diluted
Weighted-average shares outstanding, basic and diluted
Weighted Average Number Of Share Outstanding Basic And Diluted
Statement Of Stockholders Equity [Abstract]
Statement [Table]
Statement [Table]
Equity Components
Statement Equity Components [Axis]
Equity Component
Equity Component [Domain]
Common Stock
Common Stock [Member]
Additional Paid-In Capital
Additional Paid In Capital [Member]
Accumulated Deficit
Retained Earnings [Member]
Convertible Preferred Stock
Statement Class Of Stock [Axis]
Class of Stock
Class Of Stock [Domain]
Convertible Preferred Stock
Convertible Preferred Stock [Member]
Statement [Line Items]
Statement [Line Items]
Balances
Temporary Equity Balance, Shares
Temporary Equity Shares Outstanding
Temporary Equity Balance
Temporary Equity Carrying Amount Attributable To Parent
Common Stock Balance, Shares
Shares Outstanding
Exercise of stock options
Stock Issued During Period Value Stock Options Exercised
Exercise of stock options, shares
Stock Issued During Period Shares Stock Options Exercised
Stock‑based compensation
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
Net loss
Balances
Temporary Equity Balance, Shares
Temporary Equity Balance
Common Stock Balance, Shares
Accrued interest on notes payable and convertible notes payable.
Payments for proceeds from patent costs and intangible asset acquisition, net.
Payments to acquire Oncimmune.
Statement Of Cash Flows [Abstract]
Cash flows from operating activities
Net Cash Provided By Used In Operating Activities [Abstract]
Net loss
Profit Loss
Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]
Depreciation and amortization
Depreciation And Amortization
Amortization of convertible notes debt discount
Amortization Of Debt Discount Premium
Loss on extinguishment of term loan
Stock‑based compensation expense
Share Based Compensation
Change in fair value of warrant liability
Change in contingent consideration
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
Accrued interest on notes payable and convertible notes payable
Accrued Interest On Notes Payable And Convertible Notes Payable
Amortization of debt issuance costs
Amortization Of Financing Costs
Provision for doubtful accounts
Provision For Doubtful Accounts
Changes in operating assets and liabilities:
Increase Decrease In Operating Capital [Abstract]
Accounts receivable
Increase Decrease In Accounts Receivable
Other current assets
Increase Decrease In Other Current Assets
Other long-term assets and liabilities
Increase Decrease In Other Noncurrent Assets And Liabilities Net
Accounts payable and other accrued liabilities
Increase Decrease In Accounts Payable And Accrued Liabilities
Deferred revenue
Increase Decrease In Contract With Customer Liability
Net cash and cash equivalents and restricted cash used in operating activities
Net Cash Provided By Used In Operating Activities
Cash flows from investing activities
Net Cash Provided By Used In Investing Activities [Abstract]
Purchases of property and equipment
Payments To Acquire Property Plant And Equipment
Patent costs and intangible asset acquisition, net
Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net
Payment to acquire Oncimmune assets
Payments To Acquire Oncimmune
Net cash and cash equivalents and restricted cash used in investing activities
Net Cash Provided By Used In Investing Activities
Cash flows from financing activities
Net Cash Provided By Used In Financing Activities [Abstract]
Proceeds from exercise of stock options
Proceeds From Stock Options Exercised
Proceeds from term loan and notes payable
Proceeds From Issuance Of Long Term Debt
Repayment of term loan and notes payable
Repayments Of Long Term Debt
Payment of debt issuance costs
Payments Of Debt Issuance Costs
Net cash and cash equivalents and restricted cash provided by financing activities
Net Cash Provided By Used In Financing Activities
Net (decrease) increase in cash and cash equivalents and restricted cash
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
Cash, cash equivalents, and restricted cash ‑ beginning of period
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
Cash, cash equivalents, and restricted cash ‑ end of period
Organization and description of business.
Organization And Description Of Business [Abstract]
Organization and Description of Business
Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]
Recently Issued Accounting Standards
New Accounting Pronouncements And Changes In Accounting Principles [Text Block]
Fair Value Disclosures [Abstract]
Fair Value
Fair Value Disclosures [Text Block]
Balance Sheet Related Disclosures [Abstract]
Supplementary Balance Sheet Information
Supplemental Balance Sheet Disclosures [Text Block]
Debt Disclosure [Abstract]
Debt
Debt Disclosure [Text Block]
Class Of Stock Disclosures [Abstract]
Convertible Preferred Stock
Preferred Stock [Text Block]
Warrants for convertible preferred stock.
Warrants And Rights Note Disclosure [Abstract]
Warrants to Purchase Convertible Preferred Stock
Warrants For Convertible Preferred Stock [Text Block]
Revenue From Contract With Customer [Abstract]
Revenue & Accounts Receivable Credit Concentration
Revenue From Contract With Customer [Text Block]
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation
Disclosure Of Compensation Related Costs Share Based Payments [Text Block]
Earnings Per Share [Abstract]
Earnings per Share
Earnings Per Share [Text Block]
Income Tax Disclosure [Abstract]
Income Taxes
Income Tax Disclosure [Text Block]
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies
Commitments And Contingencies Disclosure [Text Block]
Basis of Presentation
Basis Of Accounting Policy Policy [Text Block]
Use of Estimates
Use Of Estimates
Concentration of Credit Risk and Other Uncertainties
Concentration Risk Credit Risk
Inventory
Inventory Supplies Policy
Fair Value of Financial Instruments
Fair Value Measurement Policy Policy [Text Block]
Summary of Fair Value of Outstanding Borrowings
Schedule Of Carrying Values And Estimated Fair Values Of Debt Instruments Table [Text Block]
Schedule of Reported Fair values of Contingent Consideration
Fair Value Liabilities Measured On Recurring Basis [Text Block]
Schedule of Changes in Contingent Consideration and Financial Liabilities
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]
Schedule of Property and Equipment
Property Plant And Equipment [Text Block]
Schedule of Intangible Assets, Excluding Goodwill
Schedule Of Intangible Assets And Goodwill Table [Text Block]
Schedule of Future Estimated Amortization Expense of Intangible Assets
Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]
Schedule of Accrued Liabilities
Schedule Of Accrued Liabilities Table [Text Block]
Summary of Long-term Notes Payable
Schedule Of Debt Instruments [Text Block]
Scheduled Principal Repayments (Maturities) of Long-term Obligations
Schedule Of Maturities Of Long Term Debt Table [Text Block]
Summary of Activity for Convertible Preferred Stock Warrants Outstanding
Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]
Summary of Revenue
Disaggregation Of Revenue Table [Text Block]
Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers
Schedules Of Concentration Of Risk By Risk Factor [Text Block]
Summary of Pre-tax Share-based Compensation Expense
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]
Summary of Stock Option Activity
Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]
Schedule of Computation of Basic and Diluted Loss per Share Attributable to Stockholders
Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]
Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]
Summary of Future Minimum Lease Payments for Operating Lease Obligations
Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]
Number of cancer test.
Number of blood based lung cancer test
Number Of Cancer Test
Number of commercial blood based test.
Number of commercial blood-based test
Number Of Commercial Blood Based Test
Number of SARS-CoV-2 test.
Number of SARS-CoV-2 test
Number Of S A R S Co V2 Test
Summary Of Significant Accounting Policies [Line Items].
Summary of significant accounting policies.
Summary Of Significant Accounting Policies [Table]
Summary Of Significant Accounting Policies [Table]
Balance Sheet Location
Balance Sheet Location [Axis]
Balance Sheet Location
Balance Sheet Location [Domain]
Other Current Assets
Other Current Assets [Member]
Summary Of Significant Accounting Policies [Line Items]
Summary Of Significant Accounting Policies [Line Items]
Restricted cash
Restricted Cash
Inventory
Other Inventory Supplies
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
Disclosure of information about liabilities measured at fair value on recurring basis.
Fair Value Liabilities Measured On Recurring Basis [Table]
Fair Value Liabilities Measured On Recurring Basis [Table]
Measurement Basis
Fair Value By Measurement Basis [Axis]
Fair Value Disclosure Item Amounts [Default]
Portion At Fair Value Fair Value Disclosure [Member]
Fair Value Measurement
Fair Value Disclosure Item Amounts [Domain]
Carrying Value
Carrying Reported Amount Fair Value Disclosure [Member]
Fair Value
Estimate Of Fair Value Fair Value Disclosure [Member]
Measurement Frequency
Fair Value By Measurement Frequency [Axis]
Measurement Frequency
Fair Value Measurement Frequency [Domain]
Fair Value, Recurring
Fair Value Measurements Recurring [Member]
Fair Value Hierarchy and NAV
Fair Value By Fair Value Hierarchy Level [Axis]
Fair Value Hierarchy and NAV
Fair Value Measurements Fair Value Hierarchy [Domain]
Level 2
Fair Value Inputs Level2 [Member]
Fair Value Liabilities Measured On Recurring Basis [Line Items]
Fair Value Liabilities Measured On Recurring Basis [Line Items]
Borrowings
Long Term Debt Fair Value
Liability Class
Fair Value By Liability Class [Axis]
Fair Value by Liability Class
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]
Contingent consideration.
Contingent Consideration
Contingent Consideration [Member]
Level 3
Fair Value Inputs Level3 [Member]
Total liabilities
Liabilities Fair Value Disclosure
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balances
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
Changes in fair value
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
Ending balances
Put option liability.
Put Option Liability
Put Option Liability [Member]
Warrant liability.
Warrant Liability
Warrant Liability [Member]
Contingent value rights.
Contingent Value Rights
Contingent Value Rights [Member]
Additions
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
Percentage of probabilities of contingent consideration successful achievement milestone discount rates range.
Business acquisition contingent consideration gross margin target period.
Business combination contingent consideration shares.
Business acquisition contingent consideration number of installments.
Business combination contingent consideration arrangements common shares redemption amount.
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Statistical Measurement
Range [Axis]
Statistical Measurement
Range [Member]
Minimum
Minimum [Member]
Maximum
Maximum [Member]
Business Acquisition
Business Acquisition [Axis]
Business Acquisition, Acquiree
Business Acquisition Acquiree [Domain]
Integrated Diagnostics, Inc.
Integrated Diagnostics, Inc
Integrated Diagnostics Inc [Member]
Investment Type
Investment Type [Axis]
Investments
Investment Type Categorization [Member]
Repurchase.
Repurchase
Repurchase [Member]
Long-term Debt, Type
Longterm Debt Type [Axis]
Long-term Debt, Type
Longterm Debt Type [Domain]
Notes payable 2018 notes.
2018 Notes
Notes Payable2018 Notes [Member]
Series G Preferred Stock
Series G Preferred Stock [Member]
Sale of Stock
Subsidiary Sale Of Stock [Axis]
Sale of Stock
Sale Of Stock Name Of Transaction [Domain]
Initial Public Offering
I P O [Member]
Counterparty Name
Counterparty Name [Axis]
Counterparty Name
Repurchase Agreement Counterparty Name [Domain]
Aveo oncology.
AVEO Oncology
A V E O Oncology [Member]
Series F Preferred Stock
Series F Preferred Stock [Member]
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Business acquisition description
Business Acquisition Description Of Acquired Entity
Business acquisition contingent consideration gross margin target
Cash Acquired From Acquisition
Business acquisition contingent consideration gross margin target period
Business Acquisition Contingent Consideration Gross Margin Target Period
Contingent consideration shares
Business Combination Contingent Consideration Shares
Contingent consideration number of installments
Business Acquisition Contingent Consideration Number Of Installments
Contingent consideration arrangements, common shares, redemption amount
Business Combination Contingent Consideration Arrangements Common Shares Redemption Amount
Contingent consideration cash payment
Payments To Acquire Businesses Net Of Cash Acquired
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range
Percentage Of Probabilities Of Contingent Consideration Successful Achievement Milestone Discount Rates Range
Put option liability current.
Put option liability
Put Option Liability Current
Warrant issued to purchase shares
Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
Warrant, exercise price
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
Warrants, expires period
Warrants And Rights Outstanding Maturity Date
Estimated air value of warrants issued
Warrants Not Settleable In Cash Fair Value Disclosure
Warrant issued to purchase shares
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
Contingent value rights shares.
Contingent value rights.
Contingent value rights percentage.
Net proceeds percentage of cash payment to the cvr holders.
Percentage of development and regulatory costs exercised using opt-out right.
Contingent value rights shares
Contingent Value Rights Shares
Contingent value rights
Contingent Value Rights
Contingent value rights percentage
Contingent Value Rights Percentage
Net proceeds percentage of cash payment to the CVR holders
Net Proceeds Percentage Of Cash Payment To C V R Holders
Percentage of development and regulatory costs exercised using opt-out right
Percentage Of Development And Regulatory Costs Exercised Using Opt Out Right
Schedule Of Property Plant And Equipment [Table]
Schedule Of Property Plant And Equipment [Table]
Long-Lived Tangible Asset
Property Plant And Equipment By Type [Axis]
Long-Lived Tangible Asset
Property Plant And Equipment Type [Domain]
Lab Equipment
Equipment [Member]
Leasehold Improvements
Leasehold Improvements [Member]
Computer Equipment
Computer Equipment [Member]
Furniture and Fixtures
Furniture And Fixtures [Member]
Software
Software And Software Development Costs [Member]
Construction in Process
Construction In Progress [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment [Line Items]
Property and equipment, gross
Property Plant And Equipment Gross
Less accumulated depreciation
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
Total property and equipment, net
Depreciation expense
Depreciation
Schedule Of Finite Lived Intangible Assets [Table]
Schedule Of Finite Lived Intangible Assets [Table]
Finite-Lived Intangible Assets by Major Class
Finite Lived Intangible Assets By Major Class [Axis]
Finite-Lived Intangible Assets, Major Class Name
Finite Lived Intangible Assets Major Class Name [Domain]
Patents
Patents [Member]
Purchased technology.
Purchased Technology
Purchased Technology [Member]
Indefinite-lived Intangible Assets
Indefinite Lived Intangible Assets By Major Class [Axis]
Indefinite-lived Intangible Assets, Major Class Name
Indefinite Lived Intangible Assets Major Class Name [Domain]
Trademarks
Trademarks [Member]
Finite Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets [Line Items]
Intangible assets subject to amortization, Cost
Finite Lived Intangible Assets Gross
Intangible assets subject to amortization, Accumulated Amortization
Finite Lived Intangible Assets Accumulated Amortization
Intangible assets subject to amortization, Net Carrying Value
Finite Lived Intangible Assets Net
Indefinite lived intangible assets excluding goodwill gross.
Intangible assets not subject to amortization, Cost
Indefinite Lived Intangible Assets Excluding Goodwill Gross
Intangible assets not subject to amortization, Net Carrying Value
Indefinite Lived Intangible Assets Excluding Goodwill
Intangible assets, Cost
Intangible Assets Gross Excluding Goodwill
Intangible assets, Accumulated Amortization
Intangible Assets Accumulated Amortization Excluding Goodwill
Intangible assets, Net Carrying Value
Amortization expense of definite-lived intangible assets
Amortization Of Intangible Assets
Remainder of 2021
Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
2022
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
2023
Finite Lived Intangible Assets Amortization Expense Year Two
2024
Finite Lived Intangible Assets Amortization Expense Year Three
2025
Finite Lived Intangible Assets Amortization Expense Year Four
2026
Finite Lived Intangible Assets Amortization Expense Year Five
Accrued clinical trial expense current.
Compensation related accruals
Employee Related Liabilities Current
Accrued clinical trial expense
Accrued Clinical Trial Expense Current
Other expenses
Other Accrued Liabilities Current
Total accrued liabilities
Debt Instruments [Abstract]
Debt Instrument [Table]
Debt Instrument [Table]
Two thousand twenty one term loan.
2021 Term Loan
Two Thousand Twenty One Term Loan [Member]
PPP loan.
PPP Loan
P P P Loan [Member]
Debt Instrument
Debt Instrument [Axis]
Debt Instrument, Name
Debt Instrument Name [Domain]
CARES act.
CARES Act
C A R E S Act [Member]
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Notes/Loan payable
Debt Instrument Carrying Amount
Unamortized debt discount and issuance costs
Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
Notes payable, total
Notes Payable
Less: current maturities
Notes Payable Current
Debt Instrument, Redemption, Period
Debt Instrument Redemption Period [Axis]
Debt Instrument, Redemption, Period
Debt Instrument Redemption Period [Domain]
Prior to First Anniversary
Debt Instrument Redemption Period One [Member]
Prior to Second Anniversary
Debt Instrument Redemption Period Two [Member]
After Second Anniversary, Prior to October 19, 2025
Debt Instrument Redemption Period Three [Member]
Thereafter
Debt Instrument Redemption Period Four [Member]
Interest-bearing Deposits
Interest Bearing Deposits [Member]
Revenue milestone.
Debt instrument frequency of periodic payment
Debt Instrument Frequency Of Periodic Payment
Revenue milestone
Revenue Milestone
Debt instrument description
Debt Instrument Description
Debt instrument prepayment penalty percentage.
Debt instrument maturity date
Debt Instrument Maturity Date
Repayments of Debt
Repayments Of Debt
Debt instrument, prepayment penalty
Debt Instrument Prepayment Penalty Percentage
Minimum liquidity ratio covenant.
Percentage of minimum revenue requirement.
Minimum liquidity ratio covenant
Minimum Liquidity Ratio Covenant
Percentage of minimum revenue requirement
Percentage Of Minimum Revenue Requirement
Debt instrument, covenant description
Debt Instrument Covenant Description
Debt instrument, percentage of stated interest rate, paid in cash.
Debt instrument, percentage of stated interest rate added to principal value of notes payable.
Debt instrument interest added to principal value.
Facility fee amount
Debt Instrument Fee Amount
Warrant issued to purchase shares
Interest rate
Debt Instrument Interest Rate Stated Percentage
Percentage of interest rate, paid in cash
Debt Instrument Percentage Of Stated Interest Rate Paid In Cash
Percentage of interest rate added to principal value of notes payable
Debt Instrument Percentage Of Stated Interest Rate Added To Principal Value Of Notes Payable
Interest added to principal value
Debt Instrument Interest Added To Principal Value
Loan principle amount
Payroll costs excludes compensation of an employee.
Percentage for non-payroll costs.
Upper limit of employee salary to reduce forgiveness.
Percentage of upper limit of employee salary to reduce forgiveness.
Payroll costs excludes compensation of an employee
Payroll Costs Excludes Compensation Of Employee
Percentage for non-payroll costs
Percentage For Non Payroll Costs
Upper limit of employee salary to reduce forgiveness
Upper Limit Of Employee Salary To Reduce Forgiveness
Percentage of upper limit of employee salary to reduce forgiveness
Percentage Of Upper Limit Of Employee Salary To Reduce Forgiveness
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
Maturities Of Long Term Debt [Abstract]
Remainder of 2021
Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
2022
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
2023
Long Term Debt Maturities Repayments Of Principal In Year Two
2024
Long Term Debt Maturities Repayments Of Principal In Year Three
2025
Long Term Debt Maturities Repayments Of Principal In Year Four
Thereafter
Long Term Debt Maturities Repayments Of Principal After Year Four
Long-term debt
Long Term Debt
Cash paid for interest
Interest Paid Net
Number of preferred stock converted into common stock.
Schedule Of Stock By Class [Table]
Schedule Of Stock By Class [Table]
Series A-1 preferred stock.
Series A-1 Preferred Stock
Series A1 Preferred Stock [Member]
Series A-2 preferred stock.
Series A2 Preferred Stock
Series A2 Preferred Stock [Member]
Series A-3 preferred stock.
Series A3 Preferred Stock
Series A3 Preferred Stock [Member]
Series B Preferred Stock
Series B Preferred Stock [Member]
Series C Preferred Stock
Series C Preferred Stock [Member]
Series D Preferred Stock
Series D Preferred Stock [Member]
Series E Preferred Stock
Series E Preferred Stock [Member]
Series H Convertible Preferred Stock
Series H Preferred Stock [Member]
Series B-1 Convertible Preferred Stock.
Series B1 Convertible Preferred Stock
Series B1 Convertible Preferred Stock [Member]
Class Of Stock [Line Items]
Class Of Stock [Line Items]
Convertible preferred stock, issued
Temporary Equity Shares Issued
Reverse stock split ratio
Stockholders Equity Note Stock Split Conversion Ratio1
Number of preferred stock converted into common stock
Number Of Preferred Stock Converted Into Common Stock
Convertible preferred stock, outstanding
Class Of Warrant Or Right [Table]
Class Of Warrant Or Right [Table]
Class of Warrant or Right
Class Of Warrant Or Right [Axis]
Class of Warrant or Right
Class Of Warrant Or Right [Domain]
Series E convertible preferred stock warrants.
Series E Convertible Preferred Stock Warrants
Series E Convertible Preferred Stock Warrants [Member]
Series G convertible preferred stock warrants.
Series G Convertible Preferred Stock Warrants
Series G Convertible Preferred Stock Warrants [Member]
Class Of Warrant Or Right [Line Items]
Class Of Warrant Or Right [Line Items]
Outstanding ‑ January 1, 2020, warrants
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
Granted, warrants
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
Forfeited/canceled, warrants
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
Exercised, warrants
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
Outstanding ‑ March 31, 2020, warrants
Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price.
Share based compensation arrangements by share based payment award non options grants in period weighted average exercise price.
Share based compensation arrangement by share based payment award non-options forfeitures and expirations in period weighted average exercise price.
Share based compensation arrangements by share based payment award non options exercises in period weighted average exercise price.
Weighted average exercise price, Outstanding ‑ January 1, 2020, warrants
Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
Weighted average exercise price, Granted
Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price
Weighted average exercise price, Forfeited/canceled
Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Exercise Price
Weighted average exercise price, Exercised
Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price
Weighted average exercise price, Outstanding ‑ March 31, 2020, warrants
Warrants to purchase shares of common stock
Warrants expiration date
Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
Disaggregation Of Revenue [Table]
Disaggregation Of Revenue [Table]
Product and Service
Product Or Service [Axis]
Product and Service
Products And Services [Domain]
Diagnostic tests.
Diagnostic Tests
Diagnostic Tests [Member]
Services
Service [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation Of Revenue [Line Items]
Advance deposits.
Concentration Risk Benchmark
Concentration Risk By Benchmark [Axis]
Concentration Risk Benchmark
Concentration Risk Benchmark [Domain]
Revenue
Sales Revenue Net [Member]
Concentration Risk Type
Concentration Risk By Type [Axis]
Concentration Risk Type
Concentration Risk Type [Domain]
Customer Concentration Risk
Customer Concentration Risk [Member]
Customer
Major Customers [Axis]
Customer
Name Of Major Customer [Domain]
Medicare.
Medicare
Medicare [Member]
Advance deposits
Advance Deposits
Revenue recognized
Contract With Customer Liability Revenue Recognized
Segment Reporting [Abstract]
Concentration Risk [Table]
Concentration Risk [Table]
The Big Ten Conference.
The Big Ten Conference
The Big Ten Conference [Member]
Pfizer, Inc.
Pfizer, Inc
Pfizer Inc [Member]
Accounts Receivable
Accounts Receivable [Member]
Centura Healthcare.
Centura Healthcare
Centura Healthcare [Member]
Purdue University.
Purdue University
Purdue University [Member]
Concentration Risk [Line Items]
Concentration Risk [Line Items]
Concentration risk, percentage
Concentration Risk Percentage1
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Plan Name
Plan Name [Axis]
Plan Name
Plan Name [Domain]
2020 equity incentive plan.
2020 Equity Incentive Plan
Two Thousand Twenty Equity Incentive Plan [Member]
Award Type
Award Type [Axis]
Award Type
Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]
Restricted Stock Units (RSUs)
Restricted Stock Units R S U [Member]
Options and restricted stock units (RSUs).
Options and Restricted Stock Units (RSUs)
Options And Restricted Stock Units R S Us [Member]
Bonus-to-options program.
Bonus-To-Options Program
Bonus To Options Program [Member]
Employee Stock Purchase Plan
Employee Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock remained available for future issuance
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Income Statement Location
Income Statement Location [Axis]
Income Statement Location
Income Statement Location [Domain]
Research and Development
Research And Development Expense [Member]
Sales, Marketing, General and Administrative
Selling General And Administrative Expenses [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total pre-tax share-based compensation expense
Allocated Share Based Compensation Expense
Stock Options, Outstanding ‑ January 1, 2021
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
Stock Options, Granted
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
Stock Options, Forfeited/canceled
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
Stock Options, Exercised
Stock Options, Outstanding ‑ March 31, 2021
Stock Options Exercisable - March 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
Weighted Average Exercise Price, Outstanding ‑ January 1, 2021
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
Weighted Average Exercise Price, Granted
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
Weighted Average Exercise Price, Forfeited/canceled
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
Weighted Average Exercise Price, Exercised
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding ‑ March 31, 2021
Weighted Average Exercise Price, Exercisable - March 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term1.
Weighted Average Contractual Life (Years), Outstanding ‑ January 1, 2021
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
Weighted Average Contractual Life (Years), Granted
Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term1
Weighted Average Contractual Life (Years), Exercisable - March 31, 2021
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
Share based compensation arrangement by share based payment award options granted aggregate intrinsic value.
Aggregate Intrinsic Value, Outstanding ‑ January 1, 2021
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
Aggregate Intrinsic Value, Granted
Share Based Compensation Arrangement By Share Based Payment Award Options Granted Aggregate Intrinsic Value
Aggregate Intrinsic Value, Outstanding ‑ March 31, 2021
Aggregate Intrinsic Value, Exercisable - March 31, 2021
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
Restricted stock units outstanding
Weighted average grant date fair value
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
Remaining unrecognized stock based compensation expense for options and RSUs
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
Amortized to expense period
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
Number of outstanding stock options granted
Weighted average exercise price,vested
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
Intrinsic value
Number of stock options granted
Weighted average exercise price, granted
Weighted average remaining contractual life, granted
Proceeds from exercise of stock options
Stock compensation expense
Number of shares reserved for issuance
Common Stock Capital Shares Reserved For Future Issuance
Shares issued
Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
Earnings Per Share Basic And Diluted Other Disclosures [Abstract]
Numerator
Net Income Loss [Abstract]
Net loss attributable to common stockholders
Denominator
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Antidilutive Securities
Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]
Antidilutive Securities, Name
Antidilutive Securities Name [Domain]
Options to purchase common stock.
Options to Purchase Common Stock
Options To Purchase Common Stock [Member]
Warrants
Warrant [Member]
Restricted Stock Units
Convertible Debt
Convertible Debt Securities [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
Provision for income taxes
Income Tax Expense Benefit
Cash paid for income taxes
Income Taxes Paid Net
Loss Contingencies [Table]
Loss Contingencies [Table]
Bdx004.
BDX004
B D X004 [Member]
Industry Sector
Equity Securities By Industry [Axis]
Industry Sector
Equity Securities Industry [Member]
Ficlatuzumab.
Ficlatuzumab
Ficlatuzumab [Member]
Nsclc poc trial.
NSCLC POC Trial
N S C L C P O C Trial [Member]
Poc clinical trials.
POC Clinical Trials
P O C Clinical Trials [Member]
Bio-rad license.
Bio-Rad License
Bio Rad License [Member]
Collaborative Arrangement and Arrangement Other than Collaborative
Type Of Arrangement [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Arrangements And Nonarrangement Transactions [Member]
Revenue share agreement.
Revenue Share Agreement
Revenue Share Agreement [Member]
Oncimmune Limited.
Oncimmune Limited
Oncimmune Limited [Member]
Loss Contingencies [Line Items]
Loss Contingencies [Line Items]
Rent expense
Operating Leases Rent Expense Net
Leases [Abstract]
Remainder of 2021
Operating Leases Future Minimum Payments Remainder Of Fiscal Year
2022
Operating Leases Future Minimum Payments Due In Two Years
2023
Operating Leases Future Minimum Payments Due In Three Years
Total
Operating Leases Future Minimum Payments Due
Percentage of development and regulatory costs.
Responsible percentage of development and regulatory costs
Percentage Of Development And Regulatory Costs
Remaining estimated obligation.
Percentage of royalty payments on net sales.
Percentage of license income generated from licensing.
Remaining estimated obligation
Remaining Estimated Obligation
Percentage of royalty payments on net sales
Percentage Of Royalty Payments On Net Sales
Percentage of license income generated from licensing
Percentage Of License Income Generated From Licensing
Percentage of royalty payments on net revenue.
License agreement expiry date.
Percentage of royalty payments on net revenue
Percentage Of Royalty Payments On Net Revenue
License expiry date
License Agreement Expiry Date
Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests.
Minimum annual volume percentage thereafter.
Period of escalations of sales.
Revenue share expenses.
Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests
Percentage Of Revenue Share Payment Related To Acquired Diagnostic Test Recognized Revenue For Non Screening Tests
Minimum annual volume percentage thereafter
Minimum Annual Volume Percentage Thereafter
Period of escalations of sales
Period Of Escalations Of Sales
Revenue share expenses
Revenue Share Expenses